The contract is for a term of one year and delivery of the products under the contract are expected to commence within the next four months. IV Clear will be used on adults and children to help protect them from infections arising as a result of intravenous catheters, such as IV catheters, central venous lines, peripherally inserted central catheters, hemodialysis catheters, other intravascular catheter and percutaneous devices.
“This contract award is massively significant for Covalon in Saudi Arabia and further strengthens Covalon as a major player in the Middle East,” said Brian Pedlar, Covalon’s CEO. “We fully expect to leverage the minimum commitment of $3.5 million into additional IV Clear revenue in Saudi Arabia. The win validates Covalon’s antimicrobial technology and will help us secure other contracts in the region and worldwide.”
IV Clear is the only antimicrobial clear silicone vascular access dressing that combines silver and chlorhexidine to provide broad-spectrum antimicrobial activity for seven days. The soft silicone adhesive provides greater patient comfort, does not macerate or damage the skin, and was shown to be up to 10 times less painful upon removal when compared to acrylic adhesives.
In addition to IV Clear, Covalon markets a full line of advanced wound management dressings for both acute and chronic wounds under its ColActive Plus and CovaWound brands. As well, Covalon is also the only provider of a dual antimicrobial silicone adhesive surgical dressing called SurgiClear, which is designed to protect surgical incisions by helping to prevent infections and medical adhesive skin injuries, while providing total incision site visibility to the healthcare provider.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that address the needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. The firm is based in Ontario, Canada.